Key terms
About PLSE
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PLSE news
Apr 03
5:23pm ET
Pulse Biosciences files to sell subscription rights to purchase up to 6M units
Mar 28
4:17pm ET
Pulse Biosciences files $50M mixed securities shelf
Mar 28
4:15pm ET
Pulse Biosciences announces $60M rights offering
Mar 08
1:19pm ET
Pulse Biosciences announces FDA 510(k) clearance for CellFX system
Feb 14
8:06am ET
Pulse: Patients treated with CellFX catheter show favorable vein isolation data
Jan 31
8:27am ET
Pulse announces findings from its CellFX nsPFA 360 cardiac catheter study
No recent press releases are available for PLSE
PLSE Financials
Key terms
Ad Feedback
PLSE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PLSE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
